Therefore, the mTOR inhibitor everolimus in combination with endocrine therapy has become a therapeutic option for HR+ advanced breast cancer (ABC) upon disease progression after first‐line anti‐hormonal therapies with or without CDK4/6 inhibitors. Here, MTOR is linked to aneurysmal bone cyst.